Posts

Friday Five: FDA steps up to counter China’s clinical‑trial edge, AbbVie buys Apogee, and psychedelics hype yields real data

on

Akeso Spotlights AML Data for Anti‑CD47 mAb Ahead of EHA 2026

on

CHARM Therapeutics Raises $80M in Oversubscribed Series B for Next-Gen Menin Inhibitor in AML

on

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

on

Amgen Acquires Oxford Spinout Dark Blue Therapeutics for Up to $840 Million, Gaining Preclinical Cancer Drug

on

FDA Approves Syndax's First-in-Class Menin Inhibitor with Black-Box Warning; Updates on GSK’s ADC Deal

on

Ipsen to Acquire ImCheck Therapeutics for €350 Million to Expand Immunotherapy Pipeline

on

Fierce Biotech Fundraising Tracker '25: CHARM attracts $80M; Wugen reels in $115M

on

Schrödinger Halts SGR-2921 Leukaemia Programme After Two Deaths

on

FDA restricts bluebird bio’s Skysona to CALD patients without suitable stem cell donors after higher blood cancer risk emerges

on

FDA tightens Skysona label, restricting use to CALD patients without alternative options due to increased blood cancer risk

on